Specialized Medical Mycology Center, Group of Applied Medical Microbiology, Federal University of Ceará, Fortaleza, Brazil.
Centers for Disease Control and Prevention, Mycotic Diseases Branch, Atlanta, Georgia, USA.
Mycoses. 2022 Mar;65(3):303-311. doi: 10.1111/myc.13404. Epub 2021 Dec 3.
Candida and Cryptococcus affect millions of people yearly, being responsible for a wide array of clinical presentations, including life-threatening diseases. Interestingly, most human pathogenic yeasts are not restricted to the clinical setting, as they are also ubiquitous in the environment. Recent studies raise concern regarding the potential impact of agricultural use of azoles on resistance to medical antifungals in yeasts, as previously outlined with Aspergillus fumigatus. Thus, we undertook a narrative review of the literature and provide lines of evidence suggesting that an alternative, environmental route of azole resistance, may develop in pathogenic yeasts, in addition to patient route. However, it warrants sound evidence to support that pathogenic yeasts cross border between plants, animals and humans and that environmental reservoirs may contribute to azole resistance in Candida or other yeasts for humans. As these possibilities could concern public health, we propose a road map for future studies under the One Health perspective.
念珠菌和隐球菌每年影响数百万人,可引起多种临床表现,包括危及生命的疾病。有趣的是,大多数人类致病性酵母菌不仅限于临床环境,因为它们在环境中也无处不在。最近的研究引起了人们对农业使用唑类药物对酵母菌中抗医学抗真菌药物的耐药性的潜在影响的关注,正如之前对烟曲霉所概述的那样。因此,我们对文献进行了叙述性综述,并提供了一些证据表明,除了患者途径之外,在致病性酵母菌中可能会出现抗唑类药物的替代环境途径。然而,需要有充分的证据来支持致病性酵母菌在植物、动物和人类之间跨界传播,并且环境储库可能有助于人类念珠菌或其他酵母菌对唑类药物的耐药性。由于这些可能性可能涉及公共卫生,我们根据“同一健康”观点提出了未来研究的路线图。